SAN FRANCISCO – While commercially available optical tools can help clinicians identify premalignant lesions in the oral cavity, the prevalence of confounding lesions increases the

With more than 1.4 million new cases of cancer diagnosed each year in the U.S. and more of these patients undergoing outpatient treatment, dental practitioners

HIV-positive head and neck cancer patients respond well to radiation therapy treatments and experience toxicity rates similar to HIV-negative patients, according to a study in

Acacia Pharma has initiated a phase I clinical study of APD515, an oromucosal formulation of an existing drug, for use in the treatment of xerostomia

A Saudi Arabian court dismissed a lawsuit filed by a man with throat cancer against a tobacco company because there was no clear-cut evidence that

Patients with pharyngeal cancer had better salivary function, less xerostomia, and improved quality of life when treated with parotid-sparing intensity-modulated radiotherapy (IMRT) rather than conventional

In his first TV interview since undergoing treatment for stage IV oropharyngeal cancer, actor Michael Douglas said his tumor is gone and that he may

A new robotic surgical procedure offers patients with oral and head and neck cancers a less invasive treatment option that preserves speech and the ability

Henry Schein Dental is now the exclusive distributor of LED Dental’s new VELscope Vx Enhanced Oral Assessment system in North America, the companies announced. The

Acetaldehyde, a flavoring compound found in many beverages and foods, appears to be a major underlying factor for the carcinogenicity of alcoholic beverages, especially for

CEL-SCI has begun a phase III clinical trial for Multikine, its flagship immunotherapy drug for head and neck cancer. The goal is to establish Multikine

Estrogen may increase the movement of precancerous cells in the mouth and thus promote the spread of the disease within the oral cavity, according to